Related Experiment Video

Updated: Apr 5, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Mechanisms of lapatinib resistance in HER2-driven breast cancer

Valentina D'Amato1, Lucia Raimondo1, Luigi Formisano1

  • 1Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli Federico II, 80131 Naples, Italy.

Cancer Treatment Reviews
|August 16, 2015
PubMed

Insights

Resistance to HER2-targeted therapies like lapatinib is a major challenge in advanced breast cancer. Understanding resistance mechanisms is key to developing new treatments and predictive markers for lapatinib response.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Targeted therapies are crucial for cancer treatment, but acquired resistance poses a significant clinical challenge.
  • HER2-positive breast cancer, characterized by ErbB2/HER2 overexpression, exhibits aggressive behavior and poor prognosis.
  • Existing HER2-targeting therapies, including lapatinib, often face eventual relapse or progression due to resistance.

Purpose of the Study:

  • To review mechanisms of intrinsic and acquired resistance to lapatinib in HER2-positive breast cancer.
  • To identify potential novel predictive markers for lapatinib response.
  • To explore new therapeutic strategies for overcoming lapatinib resistance.

Main Methods:

  • Review of preclinical studies investigating resistance mechanisms to lapatinib.
  • Analysis of clinical studies examining lapatinib response and resistance in breast cancer patients.
  • Synthesis of current knowledge on molecular pathways involved in HER2-targeted therapy resistance.

Main Results:

  • Multiple mechanisms contribute to intrinsic and acquired resistance to lapatinib.
  • Understanding these resistance pathways is crucial for predicting treatment outcomes.
  • Resistance can arise from alterations in HER2 signaling or bypass pathways.

Conclusions:

  • Elucidating lapatinib resistance mechanisms is essential for improving clinical management of HER2-positive breast cancer.
  • Identification of predictive markers could personalize lapatinib therapy.
  • Novel therapeutic strategies targeting resistance pathways are needed to enhance treatment efficacy.
Keywords:
Breast cancerErbB2/HER2LapatinibResistance

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

635
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K